DMW - Deutsche Medizinische Wochenschrift, Inhaltsverzeichnis Dtsch Med Wochenschr 2014; 139(S 01): S31-S35DOI: 10.1055/s-0033-1359956 Übersicht | Review article Kardiologie © Georg Thieme Verlag KG Stuttgart · New YorkMyokardinfarkt und kardiogener SchockMyocardial infarction and cardiogenic shockAuthors Institutsangaben M. Buerke 1 Kardiologie, Angiologie, Internistische Intensivmedizin, Medizinische Klinik II, St. Marienkrankenhaus Siegen L.S. Weilemann 2 Am Schönbornerhof 90, 55294 Bodenheim R. Blank 3 II. Medizinische Klinik, GPR Klinikum Rüsselsheim Artikel empfehlen Abstract Artikel einzeln kaufen(opens in new window)Schlüsselwörter Schlüsselwörterkardiogener Schock - Myokardinfarkt - Revaskularisation - intraaortele Ballonpumpe - Inotropika - Vasopressoren Keywords KeywordsCardiogenic shock - myocardial infarction - intraortic ballon pump - inotropic support - vasopressor support Volltext Referenzen Literatur 1 Alexander JH, Reynolds HR, Stebbins AL et al. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 2007; 297: 1657-1666 2 Annane D, Vignon P, Renault A et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 2007; 370: 676-684 3 Beurtheret S, Mordant P, Paoletti X et al. Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program). Eur Heart J 2012; 34: 112-120 4 Buerke M, Murohara T, Lefer AM. Cardioprotective Effects of a C1 Esterase Inhibitor in Myocardial Ischemia and Reperfusion. Circulation 1995; 91: 393-402 5 Buerke M, Prüfer D, Dahm M et al. Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury. J Pharmacol Exp Ther 1998; 286: 429-438 6 Buerke M, Schwertz H, Seitz W et al. Novel small molecule inhibitor of C1s exerts cardioprotective effects in ischemia-reperfusion injury in rabbits. J Immunol 2001; 167: 5375-80 7 Buerke M, Lemm H, Dietz S et al. Infarktbedingter kardiogener Schock Ursache, Diagnose und Behandlung. Intensivmed 2010; 47: 597-611 8 Cohen M, Urban P, Christenson JT et al. Intra-aortic balloon counterpulsation in US and non-US centres: results of the Benchmark(R) Registry. Eur Heart J 2003; 24: 1763-1770 9 Fuhrmann JT, Schmeisser A, Schulze MR et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med 2008; 36: 2257-2266 10 Granger CB, Mahaffey KW, Weaver WD et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003; 108: 1184-1190 11 Hannan EL, Samadashvili Z, Walford G et al. Culprit vessel percutaneous coronary intervention versus multivessel and staged percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease. JACC Cardiovasc Interv 2010; 3: 22-31 12 Hochman JS, Sleeper LA, Webb JG et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341: 625-634 13 Hochman JS, Sleeper LA, Webb JG et al. Early Revascularization and Long-term Survival in Cardiogenic Shock Complicating Acute Myocardial Infarction. JAMA 2006; 295: 2511-2515 14 Meyer J, Merx W, Dörr R et al. Successful treatment of acute myocardial infarction shock by combined percutaneous tranluminal coronary recanalization (PTCR) and percutaneous tranluminal coronary angioplasty (PTCA). Am Heart J 1982; 103: 132-134 15 Prondzinsky R, Unverzagt S, Lemm H et al. Interleukin-6, -7, -8 and -10 predict outcome in acute myocardial infarction complicated by cardiogenic shock. Clin Res Cardiol 2012; 101: 375-384 16 Prondzinsky R, Unverzagt S, Russ M et al. Hemodynamic effects of intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP shock trial. Shock 2012; 37: 378-384 17 Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation 2008; 117: 686-697 18 Rupprecht HJ, vom Dahl J, Terres W et al. Cardioprotective effects of the Na(+)/H(+) exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA. Circulation 2000; 101: 2902-2908 19 Russ MA, Prondzinsky R, Christoph A et al. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med 2007; 35: 2732-2739 20 Russ MA, Prondzinsky R, Carter JM et al. Right ventricular function in myocardial infarction complicated by cardiogenic shock: Improvement with levosimendan. Crit Care Med 2009; 37: 3017-3023 21 Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619 22 Thiele H, Schuler G, Neumann FJ et al. Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. Am Heart J 2012; 163: 938-945 23 Werdan K, Ruß M, Buerke M et al. Deutsch-österreichische S3-Leitlinie Infarktbedingter kardiogener Schock. Diagnose, Monitoring und Therapie. Intensivmedizin und Notfallmedizin 2011; 48: 291-344 24 Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501-2555
